Results for
"[search-keyword]"
Sponsor content
20 result(s) found, displaying 11 to 20
-
Prescription medicine registrationActive ingredients: tebentafusp.
-
Prescription medicine decision summaryTGA decision: KIMMTRAK (tebentafusp) is approved to treat unresectable or metastatic uveal melanoma in HLA-A*02:01 positive patient.
-
Prescription medicine decision summaryTGA decision: Truseltiq (infigratinib) is approved to treat cholangiocarcinoma.
-
Prescription medicine registrationActive ingredients: infigratinib.
-
-
-
Designation or determinationPriority review
-
-
Designation or determinationProvisional approval
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TACHOSIL human fibrinogen 5.5mg/square cm and human thrombin 2.0IU/square cm medicated sponge blister pack.